Acadia submits Nuplazid NDA, names CEO

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) submitted an NDA to FDA and requested Priority Review for Nuplazid pimavanserin to treat Parkinson's disease psychosis. The small molecule serotonin (5-HT2A) receptor inverse agonist has breakthrough therapy designation for the indication.

Acadia had hoped to submit the NDA in 1Q15, but delayed the process to prepare its commercial manufacturing systems (see BioCentury Extra, March 11). ...